Our Science


Our most advanced program, Neihulizumab, is a first-in-class antibody targeting a variety of autoimmune and immune-mediated inflammatory diseases.
The company has also developed a proprietary linker-payload platform, which successfully overcomes major obstacles in the development of antibody-drug conjugate (ADC). Our biobetter/biosuperior ADCs have shown greater antitumor activity and safety profiles.

Therapeutic Platform

Neihulizumab (AbGn-168H): Agonistic antibody with a unique mechanism of action—regulation of T cell homeostasis

Our lead inflammation drug candidate, Neihulizumab (AbGn-168H) is an immune checkpoint agonist antibody targeting PSGL-1/CD162 that regulates T cell homeostasis. This compound triggers a natural regulatory mechanism of T cell homeostasis in late stage activated T cells without affecting normal immune defenses. It has demonstrated proof-of-concept clinical efficacy in psoriasis as well as psoriatic arthritis, both of which are established T cell mediated diseases, and is currently being studied for the treatment of ulcerative colitis (phase II) and steroid refractory-acute GvHD (phase I).

Neihulizumab’s (AbGn-168H) unique mechanism of action provides a natural regulation of T cell homeostasis that induces cell death preferentially in late-stage activated T cells without affecting resting T cells and early-activated T cells. Because pathogenic T cells underlying the inflammatory conditions are usually in late-stage (chronically) activated state, eliminating this population of cells can potentially result in controlling autoimmune inflammation of T cell associated diseases, such as psoriasis, psoriatic arthritis, ulcerative colitis, multiple sclerosis, Type 1 diabetes and GvHD. Treatment with AbGn-168H could result in durable and long-term responses as the therapy is designed to eliminate the pathogenic T cells underlying these inflammatory conditions rather than simply inhibit them. In addition, since resting T cells are not affected, normal immune defenses are not impacted.


Neihulizumab (AbGn-168H): Clinical-Stage Platform in Immunology

Neihulizumab (AbGn-168H) has demonstrated signs of clinical efficacy in Psoriasis and Psoriatic Arthritis, both of which are T-cell mediated diseases, and is being studied for the treatment of Ulcerative Colitis (phase II, NCT03298022) and steroid refractory-acute GvHD (phase I, NCT03327857).


Proprietary ADC-linker and biosuperior ADCs

Antibody-drug conjugate (ADC) delivers a potent “missile” to targeted tumor cells and is currently the most efficacious agent known for cancer therapy. Many ADCs have been clinically tested but a large portion of them failed due to toxic side effects caused by on-target toxicity, which is determined by the targeting antibody. The targeting antibodies used in our biosuperior ADCs have all been clinically validated for their safety. This early stringent selection of targeting antibodies significantly eliminates the risk of toxicity in the downstream development of our biobetter/biosuperior ADC candidates. As a result, our best-in-class ADCs have potential to achieve a successful clinical outcome.


Our ADC platform includes three prominent features that are able to significantly improve the therapeutic index of drugs when combined:

1 Cancer specific antibody
2 Proprietary linker design plus potent warhead
3 Special conjugation sites significantly enhance the stability and safety of ADCs


Clinical-Stage ADC Platform in Oncology

Our lead ADC candidate, AbGn-107, is currently being tested in treating chemo-refractory gastric, pancreatic, colorectal and biliary cancers (NCT02908451).


About Antibody-Drug Conjugate

Monoclonal Antibody

Preferentially targets tumor-specific or tumor-associated antigens


Connects cytotoxins with an antibody and releases the payload only in the target cell


A small molecule drug conjugate that is more efficacious than regular chemo-therapeutics

1Cancer Ag engaged by specific ADC to initiate the internalization

2Protease Cleavage to release super toxin within the cellt

3Super toxins act at microtubule, DNA or other vital cellular component to result in cell cycle arrest or apoptosis



Evaluation, Validation and Dissemination of ideas.



We are committed to responsible intellectual property management, creating a strong foundation for innovation.

In an effort to protect and expand our intellectual property portfolio, AltruBio actively pursues domestic and international patents for any commercially valuable inventions.